Spontaneous Pregnancy After Fertility-sparing Surgery and Adjuvant Chemotherapy for Advanced Pure Dysgerminoma: A Case Report

Overview

Journal Clin Case Rep

Date 2024 Jun 3

PMID 38827934

Authors

Goksu Goc

Alida Goc

Gezim Kastrati

Dardan Baftiu

Fisnik Kurshumliu

Affiliations

Soon will be listed here.

Abstract

Key Clinical Message: Fertility-sparing surgery and appropriate adjuvant chemotherapy for advanced malignant ovarian germ cell tumors have excellent survival results and promising reproductive and obstetric outcomes.

Abstract: This case report aims to demonstrate the potential feasibility and success of fertility-sparing surgery (FSS) coupled with adjuvant chemotherapy in treating advanced malignant ovarian germ cell tumor (MOGCT), focusing on pure dysgerminoma, fertility, and achieving spontaneous pregnancy. The patient was a 23-year-old female who initially presented with complaints of abdominal distension and a palpable mass and was subsequently diagnosed with advanced MOGCT. The patient provided a complete clinical and radiological response to FSS with complete surgical staging and cisplatin-based chemotherapy (bleomycin, etoposide, and cisplatin). Despite being diagnosed with advanced MOGCT and treated with FSS and adjuvant chemotherapy, she later experienced spontaneous pregnancy, giving birth to a healthy child. This case study demonstrated the potential for successful fertility preservation and pregnancy in advanced-stage MOGCT patients treated with personalized treatment approaches. Nevertheless, a broader investigation is needed to understand the relevant complex dynamics and to ascertain whether FSS with adjuvant chemotherapy could be a reliable approach in treating advanced MOGCT.

Citing Articles

Spontaneous pregnancy after fertility-sparing surgery and adjuvant chemotherapy for advanced pure dysgerminoma: A case report.

Goc G, Goc A, Kastrati G, Baftiu D, Kurshumliu F Clin Case Rep. 2024; 12(6):e9020.

PMID: 38827934 PMC: 11139637. DOI: 10.1002/ccr3.9020.

References

Goc G, Goc A, Kastrati G, Baftiu D, Kurshumliu F . Spontaneous pregnancy after fertility-sparing surgery and adjuvant chemotherapy for advanced pure dysgerminoma: A case report. Clin Case Rep. 2024; 12(6):e9020. PMC: 11139637. DOI: 10.1002/ccr3.9020. View

Ayhan A, Tunc M, Akilli H, Haberal N, Haberal A . Fertility-sparing approach to malignant ovarian germ cell tumors - Oncologic and obstetric outocome: A retrospective study. Int J Gynaecol Obstet. 2023; 164(3):1074-1079. DOI: 10.1002/ijgo.15141. View

Kilic C, Cakir C, Yuksel D, Kilic F, Kayikcioglu F, Koc S . Ovarian Dysgerminoma: A Tertiary Center Experience. J Adolesc Young Adult Oncol. 2020; 10(3):303-308. DOI: 10.1089/jayao.2020.0087. View

Chu R, Liu P, Chen J, Cheng X, Li K, Che Y . Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study. J Gynecol Oncol. 2023; 34(2):e12. PMC: 9995871. DOI: 10.3802/jgo.2023.34.e12. View

Boussios S, Moschetta M, Tatsi K, Tsiouris A, Pavlidis N . A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: Diagnostic and therapeutic perspectives. J Adv Res. 2018; 12:1-9. PMC: 6032492. DOI: 10.1016/j.jare.2018.02.006. View

Saani I, Raj N, Sood R, Ansari S, Mandviwala H, Sanchez E . Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours. Int J Environ Res Public Health. 2023; 20(12). PMC: 10298722. DOI: 10.3390/ijerph20126089. View

A L Husaini H, Soudy H, El Din Darwish A, Ahmed M, Eltigani A, A L Mubarak M . Pure dysgerminoma of the ovary: a single institutional experience of 65 patients. Med Oncol. 2012; 29(4):2944-8. DOI: 10.1007/s12032-012-0194-z. View

Goyal L, Kaur B, Goyal G, Rajora P . Unusual Cases of Pure Malignant Germ Cell Tumors of the Ovary: A Case Series on 10 Years Experience at a Tertiary Care Center. J Reprod Infertil. 2022; 22(4):267-273. PMC: 8669411. DOI: 10.18502/jri.v22i4.7652. View

Zamani N, Rezaei Poor M, Ghasemian Dizajmehr S, Alizadeh S, Modares Gilani M . Fertility sparing surgery in malignant ovarian Germ cell tumor (MOGCT): 15 years experiences. BMC Womens Health. 2021; 21(1):282. PMC: 8336352. DOI: 10.1186/s12905-021-01437-8. View

10.

Nasioudis D, Frey M, Chapman-Davis E, Caputo T, Holcomb K . Fertility-preserving surgery for advanced stage ovarian germ cell tumors. Gynecol Oncol. 2017; 147(3):493-496. DOI: 10.1016/j.ygyno.2017.10.010. View

11.

Akasaka M, Hirai T, Yoshida K, Kondo E, Ikeda T, Iwamoto T . Association between cumulative cisplatin dose and reproductive and sexual functions in patients with malignant ovarian germ cell tumors treated with bleomycin, etoposide, and cisplatin therapy: a case series study. J Pharm Health Care Sci. 2022; 8(1):33. PMC: 9673296. DOI: 10.1186/s40780-022-00265-8. View

12.

Liu Q, Ding X, Yang J, Cao D, Shen K, Lang J . The significance of comprehensive staging surgery in malignant ovarian germ cell tumors. Gynecol Oncol. 2013; 131(3):551-4. DOI: 10.1016/j.ygyno.2013.08.016. View

13.

Turkmen O, Karalok A, Basaran D, Comert Kimyon G, Tasci T, Ureyen I . Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors. J Adolesc Young Adult Oncol. 2017; 6(2):270-276. DOI: 10.1089/jayao.2016.0086. View

14.

Solheim O, Trope C, Rokkones E, Kaern J, Paulsen T, Salvesen H . Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era". Gynecol Oncol. 2014; 136(2):224-9. DOI: 10.1016/j.ygyno.2014.12.010. View

15.

Rungoutok M, Suprasert P . Oncology and reproductive outcomes over 16 years of malignant ovarian germ cell tumors treated by fertility sparing surgery. World J Clin Oncol. 2022; 13(10):802-812. PMC: 9630996. DOI: 10.5306/wjco.v13.i10.802. View

16.

Ghalleb M, Bouzaiene H, Slim S, Hadiji A, Hechiche M, Ben Hassouna J . Fertility-sparing surgery in advanced stage malignant ovarian germ cell tumor: a case report. J Med Case Rep. 2017; 11(1):350. PMC: 5733088. DOI: 10.1186/s13256-017-1516-8. View

17.

Xu T, Sun F, Li Y . Long-Term Outcomes and Factors Related to the Prognosis of Pure Ovarian Dysgerminoma: A Retrospective Study of 107 Cases. Gynecol Obstet Invest. 2021; 86(6):494-501. DOI: 10.1159/000519515. View

18.

Sagnic S, Karadag C, Tuncer H, Dogan S, Simsek T . Reproductive and oncologic outcomes in women with non-epithelial ovarian cancer: Single center experience over 25 years. Turk J Obstet Gynecol. 2023; 20(2):97-104. PMC: 10236224. DOI: 10.4274/tjod.galenos.2023.98036. View

19.

Tamauchi S, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K . Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study. Am J Obstet Gynecol. 2018; 219(4):385.e1-385.e7. DOI: 10.1016/j.ajog.2018.07.021. View

20.

Maidarti M, Garinasih P, Anggraeni T . Conservative surgical staging as a means to preserve fertility in patients with dysgerminoma: a case report. Ann Med Surg (Lond). 2023; 85(3):427-430. PMC: 10010807. DOI: 10.1097/MS9.0000000000000146. View